Bruce I. Sachs - Apr 12, 2023 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
Director
Signature
/s/Christiana Stevenson, Attorney-in-Fact
Stock symbol
VRTX
Transactions as of
Apr 12, 2023
Transactions value $
-$5,422,840
Form type
4
Date filed
4/14/2023, 04:14 PM
Previous filing
Feb 2, 2023
Next filing
Apr 18, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Options Exercise $1.54M +21.3K +51.69% $72.14* 62.5K Apr 12, 2023 Direct
transaction VRTX Common Stock Sale -$950K -2.92K -4.67% $325.65 59.6K Apr 12, 2023 Direct F1, F2, F3
transaction VRTX Common Stock Sale -$3.38M -10.4K -17.38% $326.46 49.2K Apr 12, 2023 Direct F1, F2, F4
transaction VRTX Common Stock Sale -$2.63M -8.03K -16.3% $327.48 41.2K Apr 12, 2023 Direct F1, F2, F5
transaction VRTX Common Stock Gift $0 -1.21K -2.94% $0.00 40K Apr 13, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRTX Stock Option (Right to Buy) Options Exercise $0 -21.3K -100% $0.00* 0 Apr 12, 2023 Common Stock 21.3K $72.14 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1, which was entered into on 11/04/2022.
F2 Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3 Open market sales reported on this line occurred at a weighted average price of $325.65 (range $325.00 to $325.99).
F4 Open market sales reported on this line occurred at a weighted average price of $326.46 (range $326.00 to $326.97).
F5 Open market sales reported on this line occurred at a weighted average price of $327.48 (range $327.00 to $327.93).
F6 Fully vested